Andrew is working with ABC2 as part of his post-doctoral fellowship at the UNC Eshelman School of Pharmacy. During his last eight years of graduate and post-doctoral research, Andrew has focused on targeted drug delivery and its ability to revolutionize cancer therapy by maximizing tumor uptake and minimizing side effects. He initially worked on formulating and delivering nanoparticles for cancer therapy, and now is engineering stem cells to provide targeted treatment for glioblastoma (GBM), the most common and aggressive brain cancer. The majority of his studies have taken place in in vivo mouse models, and he is currently helping lead a multi-university initiative to update and optimize live brain slice technology for GBM research.
As a brain cancer survivor himself, Andrew has felt a special connection to his research since his transition into the Hingtgen Lab at UNC in 2016 and his subsequent partnership with ABC2. It is a powerful experience to perform animal work using the same surgical techniques and chemotherapies that were used during his brain cancer treatment in 2008. It has been even more satisfying to partner with ABC2 to help improve therapeutics for others.